Loading…
← CockpitCompetitor Analysis › 688739.SS Liaoning Chengda Biotechnology Co. Ltd. Class AOpen in the cockpit ↗

Liaoning Chengda Biotechnology Co. Ltd. Class A688739.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese vaccine maker and one of China's largest producers of human rabies vaccine.

Momentum leader 81
Mkt cap
$1.22B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$4.76M
20-day average traded
Fwd P/E
44.0×
forward earnings
ROIC−WACC
-4.5 pp
WACC 7.5%
Hurdle
+14 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥19.94
1D-0.3%
1W-4.0%
1M-1.5%
3M-4.3%
6M-13.7%
YTD-22.6%
1Y-27.5%
ATR %1.9%
52w lowhigh29.9% off high

What Liaoning Chengda Biotechnology does

Chinese vaccine maker and one of China's largest producers of human rabies vaccine.

Rabies shots in China are largely self-paid rather than part of a government immunisation programme, so sales go through provincial disease-control centres and clinics to people treated after animal bites. The company depends heavily on this one vaccine category and is trying to develop others.

Products and services

  • Human rabies vaccine
  • Other vaccines

Customers

  • CDC/vaccination centers
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines

What could go right

  • Rabies vaccination demand (pet ownership growth)

What could go wrong

  • Vaccine pricing pressure
  • Safety-incident regulatory risk

Moat: narrow (scale, regulatory licence, brand). Long-established, large-scale rabies-vaccine production base and brand recognition in China.

Headquarters: Shenyang, China · Employees: 1,781

Named competitors

Liaoning Chengda Biotechnology at a glance

Size Liaoning Chengda Biotechnology (688739.SS) is a China Health Care company (Biotechnology) with a market value of $1.22B, the 1823rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.94 on 18 Nov 2026.

Performance Over six months the shares fell 13.7%, against -22.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue fell 9.0% over the last twelve months (peer median +13.0%); the operating margin is -0.5% (peer median -120.9%).

Valuation It trades at 44.0× forward earnings against a peer median of 32.5× (3rd most expensive of 7).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.5 points below its cost of capital (7.5% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026688739.SS 87Peer median 76
Six months, rebased to 100: Liaoning Chengda Biotechnology against the median of its 20 peers (local-currency closes).

Liaoning Chengda Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.34BCN¥1.39BCN¥1.67BCN¥1.74BCN¥1.81B
Revenue growth—-17%-4%-4%—
Gross profitCN¥1.09BCN¥961MCN¥1.25BCN¥1.35BCN¥1.47B
EBITDAn/aCN¥319MCN¥572MCN¥638MCN¥862M
Net incomeCN¥65.0MCN¥132MCN¥343MCN¥466MCN¥714M
Free cash flowCN¥222MCN¥59.9MCN¥166MCN¥158MCN¥110M
Capital expenditureCN¥160MCN¥308MCN¥362MCN¥552MCN¥512M
Total debtCN¥11.2MCN¥9.37MCN¥15.1MCN¥20.0MCN¥21.9M

Quarterly statements and history in the cockpit →

Liaoning Chengda Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%MLYSAKUMS000403301207CMPSTSHANVAXNUVBVOR4588JBIO9606688739.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Liaoning Chengda Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×50×100×AKUMS000403301207NVAX6185ANAB688739.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Liaoning Chengda Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%AKUMS301207ANAB688739.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Liaoning Chengda Biotechnology is the large dot.

Liaoning Chengda Biotechnology competitors and peer comparison

Head to head with its named competitors (688739.SS vs 688276.SS vs 300142.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Liaoning Chengda Biotechnology 688739.SS$1.22B-14%-9%0%44.0×6.6%
Changchun BCHT Biotechnology 688276.SS$992M-2%+2%-29%n/an/a
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%348.7×29.5%

How Liaoning Chengda Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Liaoning Chengda Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure688739.SSPeer medianRank in peer set
1-month return-1.5%-16.8%5th highest of 21
6-month return-13.7%-22.3%4th highest of 19
Distance from 52-week high-29.9%-49.0%3rd highest of 21
Revenue growth (TTM)-9.0%+13.0%4th lowest of 14
Operating margin-0.5%-120.9%4th highest of 15
Forward P/E44.0×32.5×3rd most expensive of 7
Growth the price implies (Req g, 7 yrs)6.6%15.3%2nd least demanding of 4
Growth delivered (Del g)-7.0%+9.9%2nd lowest of 4
Hurdle (Req g minus delivered)+13.6 pp+5.5 pp2nd most demanding of 4
ROIC minus cost of capital-4.5 pp-8.0 pp4th highest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%44.0×6.6%-7.0%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%25.6×15.3%+9.9%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%26.5×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%38.6×33.2%-13.1%
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%60.5×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%n/an/an/a

Questions

Who are Liaoning Chengda Biotechnology's main competitors?
Named competitors: Changchun BCHT Biotechnology (688276.SS), Walvax Biotechnology (300142.SZ). The cockpit's measured peer set (industry) also includes Mineralys Therapeutics (MLYS), Akums Drugs and Pharmaceuticals (AKUMS.NS), Pacific Shuanglin Bio-pharmacy (000403.SZ), Hualan Biological Vaccine (301207.SZ), Kardigan (KARD), COMPASS Pathways Plc Sponsored ADR (CMPS).
Is Liaoning Chengda Biotechnology expensive compared with its peers?
On forward p/e it trades at 44.0× against a peer median of 32.5×, 3rd most expensive of 7 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Liaoning Chengda Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -13.7% against -22.3% for the median peer; over one year -27.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.